Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 17/20 | 0.51 |
| ▸ | PPARD | Q03181 | 9/20 | 0.51 |
| ▸ | PPARG | P37231 | 8/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8653853 | 0.92 | ALDH1A1 (0.50) | PPARAPPARDPPARGFFAR1FFAR4 | |
| SCHEMBL7079111 | 0.85 | PPARA (0.48) | PPARAPPARDPPARGLTA4H | |
| SCHEMBL8959117 | 0.83 | LTA4H (0.62) | PPARAPPARDPPARGLTA4H | |
| SCHEMBL8658206 | 0.81 | PPARD (0.45) | PPARAPPARDPPARGFFAR1FFAR4 | |
| SCHEMBL8841070 | 0.80 | PPARA (0.52) | PPARAPPARDPPARGFFAR1FFAR4 | |
| SCHEMBL9167963 | 0.79 | PPARA (0.44) | PPARAPPARDPPARGLTA4H | |
| SCHEMBL9165238 | 0.79 | MEN1 (0.52) | PPARAPPARDPPARG | |
| SCHEMBL5990060 | 0.79 | CYP1A2 (0.51) | PPARAPPARDPPARG | |
| SCHEMBL8865546 | 0.78 | CYP1A2 (0.47) | PPARAPPARDPPARG | |
| SCHEMBL5375018 | 0.78 | LTA4H (0.68) | PPARALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6645997-B2 | Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| US-20020082292-A1 | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082292-A1 | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | PPARD, PPARA, PPARG | PPARA 2/4885PPARD 1/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.